173472-42-9

Usage

Uses

Used in Pharmaceutical Industry:
(S)-3-BOC-AMINO-1-DIAZO-5-METHYLTHIO-2-PENTANONE is used as a reagent for the synthesis of drug intermediates and active pharmaceutical ingredients. Its unique structure allows for the protection of amino groups and enhances reactivity and selectivity in various chemical reactions, making it a valuable compound in the development of new drugs.
It is important to handle and use (S)-3-BOC-AMINO-1-DIAZO-5-METHYLTHIO-2-PENTANONE with caution due to its potential hazards and risks associated with diazo compounds. Proper safety measures and protocols should be followed to minimize any risks during its use in the pharmaceutical industry.

Upstream product

• 186581-53-3 diazomethane 
• 2488-15-5 N-tert-butoxycarbonyl-L-methionine 

Downstream Products

• 244251-20-5 (S)-3-{[(tert-butoxy)carbonyl]amino}-5-(methylsulfanyl)pentanoic acid 
• 173472-40-7 N-[(S)-4-(tert-Butyl-diphenyl-silanyloxy)-1-(2-{3-[(R)-1-(2-methylsulfanyl-ethyl)-3-triethylsilanyloxy-propyl]-thioureido}-ethyl)-butyl]-4-methyl-benzenesulfonamide 
• 173472-41-8 (2S,8S)-2-[3-(tert-Butyl-diphenyl-silanyloxy)-propyl]-1-(toluene-4-sulfonyl)-8-(2-triethylsilanyloxy-ethyl)-1,3,4,6,7,8-hexahydro-2H-pyrimido[1,2-a]pyrimidine 

Relevant academic research and scientific papers

Synthesis of enantiopure dehydropiperidinones from α-amino acids and alkynes via azetidin-3-ones

Chiral dehydropiperidinones were synthesized in enantiopure form from α-amino acids and alkynes via azetidin-3-ones.

Synthesis of cyclo-β-tripeptides and their biological in vitro evaluation as antiproliferatives against the growth of human cancer cell lines

A number of cyclo-β-tripeptides and their linear precursors were subjected to primary biological evaluation for cancer-cell growth inhibition (one-dose, three-cell essay), and the five most active ones were then tested in the anti-tumor screen of the National Cancer Institute (Bethesda, USA) with 60 human cancer cell lines. Growth inhibition values GI50 in the one-digit micromolar, and in one case in the nanomolar range were obtained. The effects show selectivities for certain types of cancer cells and for certain cell lines within these types; the screen includes leukemia, non-small-cell lung, colon, and central-nervous-system (CNS) cancer, melanoma, ovarian, renal, prostate, and breast cancer cell lines. The synthesis and full characterization of two new cyclo-β-peptides, (β3-HSer(OBn))3 (11) and (β3-HMet)3 (12) are described. Other cyclo-β-peptides included in this investigation are (βAsp(Bn))3 (13), (β-HGlu(Bn))3 (14), and (β-HAla)3 (16), compounds which had been previously prepared by us. Strongest activities were measured with the cyclo-β-peptides bearing benzyl-ester or benzyl-ether groups in the side chains. The cytotoxic activity of the compounds included in this investigation is much lower (LC50 > 100 μM) than their antiproliferative activity (GI50).

The synthesis of di(hydroxyalkyl) substituted bicyclic guanidines

The synthesis of the enantiomerically pure bicyclic guanidines 3a and 3b is described.The convergent strategy is based on methodology developed by Schmidtchen.The therefore required amine components 6 and 9 obtained from methionine and L-glutamic acid, respectively.

Synthesis of a Chiral Di(hydroxyalkyl) Substituted Bicyclic Guanidine

Schmidtchen's methodology is used successfully for the synthesis of the chiral disubstituted bicyclic guanidinium salt 2.The two therefore required primary amine compounds 6 and 9 are obtained from L-methionine and L-glutamic acid, respectively.